Exhibit 10.1

KaloBios Pharmaceuticals, Inc.
1000 Marina Blvd., Suite 250
Brisbane, CA 94005

March 21, 2017

Blackhorse Capital LP
Blackhorse Capital Master Fund Ltd.
Blackhorse Capital Management LLC
c/o Opus Equum, Inc.
P.O. Box 788
Dolores, Colorado 81323

Cheval Holdings, Ltd.
P.O. Box 309G
Ugland House,
Georgetown, Grand Cayman Islands KY1-1104

Nomis Bay LTD
Penboss Building
50 Parliament Street
Hamilton, Bermuda HM12

Re:          Amendment to Credit and Security Agreement, dated as of December
21, 2016

Ladies and Gentlemen:

Reference is made to the Credit and Security Agreement (the “Credit Agreement”),
dated as of December 21, 2016, by and between KaloBios Pharmaceuticals, Inc.
(the “Borrower”) and Black Horse Capital LP, Black Horse Capital Master Fund
Ltd., Cheval Holdings, Ltd., and Nomis Bay LTD (each a “Lender” and
collectively, the “Lenders”), pursuant to which the Lenders loaned the principal
amount of $3,315,217 to the Company. Capitalized terms used but not defined
herein have the meanings given to them in the Agreement.

Pursuant to our prior discussions, the Company desires to borrow an additional
amount of $5,978,260.00 (the “Additional Amount”) and the Lenders desire to lend
the Additional Amount to the Company on the terms and conditions set forth in
the Agreement, including an upfront fee of $478,260 and a commitment fee of
$275,000 and hereby agree as follows:

1.
Each Lender shall make an additional term loan to the Company on the date of
this amendment (the “Closing Date”) in the amount identified in Exhibit I (the
Lender Amount).

 
 

--------------------------------------------------------------------------------

 

2.
The portion of the Additional Amount made by each Lender shall be evidenced by a
promissory note (the “Promissory Note”) executed by Borrower for the Lender
Amount and delivered on the Closing Date.

3.
Each Promissory Note shall bear interest at the Fixed Rate specified in the
Agreement and shall be subject to the Default Interest Rate upon the occurrence
of an Event of Default as defined in the Agreement.

4.
The Form of the Promissory Note is attached hereto as Exhibit II

5.
Except as specifically provided in this amendment and as the context of this
amendment otherwise may require to give effect to the intent and purposes of
this amendment, the Agreement shall remain in full force and effect without any
other amendments or modifications.

6.
This amendment may be executed in two or more counterparts, all of which when
taken together shall be considered one and the same agreement. In the event that
any signature is delivered by facsimile transmission or by e-mail delivery of a
“.pdf” format data file, such signature shall create a valid and binding
obligation of the party executing (or on whose behalf such signature is
executed) with the same force and effect as if such facsimile or “.pdf”
signature page were an original thereof.

7.
This amendment shall be governed by, and construed and enforced in accordance
with, the internal laws of the State of Delaware, without regard to the
principles of conflicts of law thereof.

[Signature Page Follows]
 
2

--------------------------------------------------------------------------------

 

 
Very truly yours,
                           
KALOBIOS PHARMACEUTICALS, INC.
                   
By:
/s/ Cameron Durrant, M.D.
     
Name: Cameron Durrant, M.D.
     
Title:   Chief Executive Officer
 

ACKNOWLEDGED AND AGREED:

BLACK HORSE CAPITAL LP
                   
By:
/s/ Dale Chappell
   
Name: Dale Chappell
   
Title:   Manager of the GP
 

 
BLACK HORSE CAPITAL MASTER FUND LTD.
                   
By:
/s/ Dale Chappell
   
Name: Dale Chappell
   
Title:   Director
 

 
CHEVAL HOLDINGS, LTD.
                   
By:
/s/ Dale Chappell
   
Name: Dale Chappell
   
Title:   Director
 

 
NOMIS BAY LTD
                   
By:
/s/ James Keyes
   
Name: James Keyes
   
Title:   Director
 

 
3

--------------------------------------------------------------------------------

 
Exhibit I
Lender Amounts

Lender
 
Term Loan Commitment Amount
 
Term Loan Commitment Percentage
Nomis Bay LTD
 
$2,989,130
 
50.00%
Black Horse Capital Master Fund Ltd.
 
$1,195,652
 
20.00%
Cheval Holdings, Ltd.
 
$1,281,141
 
21.43%
Black Horse Capital LP
 
$512,337
 
8.57%
TOTALS
 
$5,978,260
 
100%

4

--------------------------------------------------------------------------------

 
Exhibit I
Form of Promissory Note

TERM LOAN NOTE
 
$____________
March__, 2017

FOR VALUE RECEIVED, KALOBIOS PHARMACEUTICALS, INC., a Delaware corporation
(“Borrower”), hereby unconditionally promises to pay to the order of
_____________, a _____________ (together with its successors and assigns,
“Lender”) at the office of Lender at ____________________, or at such other
place as Lender may from time to time designate in writing to Borrower, in
lawful money of the United States of America and in immediately available funds,
the principal sum of ________________ and No/100 Dollars ($____________) or, if
less, the aggregate unpaid principal amount of the portion of the Term Loan made
by Lender to Borrower under the terms of that certain Credit and Security
Agreement, dated as of December 21, 2016 (as amended, restated, supplemented or
otherwise modified from time to time, the “Credit Agreement”), by and among
Borrower, Lender, various other lenders as are, or may from time to time become,
parties thereto as “Lenders” (including without limitation, Lender) and Black
Horse Capital Master Fund Ltd., individually as a Lender, and as administrative
agent (in such capacity and together with its successors and assigns, “Agent”). 
All capitalized terms used herein (which are not otherwise specifically defined
herein) shall be used in this Term Loan Note (this “Note”) as defined in the
Credit Agreement.
 
1.          The outstanding principal balance of the Term Loan evidenced by this
Note shall be due and payable or otherwise satisfied in full on the Termination
Date or the Maturity Date in accordance with the terms of the Credit Agreement.
 
2.          This Note is issued in accordance with the provisions of the Credit
Agreement and is entitled to the benefits and security of the Credit Agreement
and the other Financing Documents, and reference is hereby made to the Credit
Agreement for a statement of the terms and conditions under which the Term Loan
evidenced hereby were made and are required to be repaid.  In the event of any
conflict between the terms of this Note and the terms of the Credit Agreement,
the terms of the Credit Agreement shall prevail.
 
3.          Borrower promises to pay interest from the date hereof until payment
in full hereof on the unpaid principal balance of the Term Loan evidenced hereby
at the per annum rate or rates set forth in the Credit Agreement.  Interest on
the unpaid principal balance of the Term Loan evidenced hereby shall be payable
on the dates and in the manner set forth in the Credit Agreement.  Interest as
aforesaid shall be calculated in accordance with the terms of the Credit
Agreement.
 
4.          Upon and after the occurrence and during the continuation of an
Event of Default, and as provided in the Credit Agreement, the Term Loan
evidenced by this Note may be declared, and shall thereupon immediately become,
due and payable without presentment, demand, protest, notice, or legal process
of any kind whatsoever.
 
5.          Payments received in respect of the Term Loan shall be applied as
provided in the Credit Agreement.
 
5

--------------------------------------------------------------------------------

 
6.          Presentment, demand, protest and notice of presentment, demand,
nonpayment and protest are each hereby waived by Borrower as provided in the
Credit Agreement.
 
7.          No waiver by Agent or any Lender of any one or more defaults by the
undersigned in the performance of any of its obligations under this Note shall
operate or be construed as a waiver of any future default or defaults, whether
of a like or different nature, or as a waiver of any obligation of Borrower to
any other Lender under the Credit Agreement.
 
8.          No provision of this Note may be amended, waived or otherwise
modified unless such amendment, waiver or other modification is in writing and
is signed or otherwise approved by Borrower, the Required Lenders and any other
Lender under the Credit Agreement to the extent required under Section 10.15 of
the Credit Agreement.  No failure or delay on the part of any Lender in
exercising any right, power, or remedy under this Note (including, without
limitation, the right to declare this Note due and payable) shall operate as a
waiver of such right, power, or remedy.
 
9.          THIS NOTE SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED
IN ACCORDANCE WITH THE LAWS OF THE STATE OF DELAWARE WITHOUT REGARD TO CONFLICTS
OF LAW PRINCIPLES.
 
10.          Whenever possible each provision of this Note shall be interpreted
in such manner as to be effective and valid under applicable law, but in case
any provision of or obligation under this Note shall be invalid, illegal or
unenforceable in any jurisdiction, the validity, legality and enforceability of
the remaining provisions or obligations, or of such provision or obligation in
any other jurisdiction, shall not in any way be affected or impaired thereby.
 
11.          Whenever in this Note reference is made to Agent, Lenders or
Borrower, such reference shall be deemed to include, as applicable, a reference
to their respective successors and assigns.  The provisions of this Note shall
be binding upon Borrower and its successors and assigns except that Borrower may
not assign any of its rights or delegate any of its obligations under this Note
without the prior written consent of Lenders.  This Note shall inure to the
benefit of Lender and its successors and assigns.
 
12.          In addition to and without limitation of any of the foregoing, this
Note shall be deemed to be a Financing Document and shall otherwise be subject
to all of the general terms and conditions contained in Article 11 of the Credit
Agreement, mutatis mutandis.
 

[SIGNATURES APPEAR ON FOLLOWING PAGE(S)]
 
6

--------------------------------------------------------------------------------

 
IN WITNESS WHEREOF, intending to be legally bound, and intending that this Note
constitutes an agreement executed under seal, the undersigned has executed this
Note under seal as of the day and year first hereinabove set forth.
 
BORROWER:
KALOBIOS PHARMACEUTICALS, INC.
                   
By:
      Name:
Dr. Cameron Durrant
    Title:
Chairman and Chief Executive Officer
                   
Address for Borrower:
         
1000 Marina Blvd #250
Brisbane, CA 94005-1878
Attn:  Dr. Cameron Durrant
   
Facsimile:  
     
E-Mail:  camerondurrant@yahoo.com
 

 
7

--------------------------------------------------------------------------------